Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations.
Work-related problems in multiple sclerosis: a literature review on its associates and determinants.
Multiple sclerosis as a cause of the acute vestibular syndrome.
MicroRNA-21 with therapeutic potential in autoimmune diseases.
Low body weight linked to PML risk with natalizumab in MS
Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.
Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis.
Acute Transverse Myelitis Associated With Human Parvovirus B19 Infection.
ISENTRESS® prescribing information
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
Molecular triggers of neuroinflammation in mouse models of demyelinating diseases.
[Autonomic nervous system alteration in multiple sclerosis patients with urinary symptoms. Clinical, urodynamic and cardiovascular study].
SIRT1 is decreased during relapses in patients with multiple sclerosis.
Pelizaeus-Merzbacher disease-associated proteolipid protein 1 inhibits oligodendrocyte precursor cell differentiation via extracellular-signal regulated kinase signaling.
[Ophthalmological Findings in Paediatric and Adolescent Multiple Sclerosis.]
Multiple Large Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and Therapeutic Challenge.
Central nervous system B-cell lymphoma in multiple sclerosis.
Anti-aquaporin-4 IgG in Patients Presenting with Unilateral Optic Neuritis: A Cohort Study.
Association of circulating follicular helper T cells with disease course of NMO spectrum disorders.
Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: Preliminary findings of a randomized, placebo-controlled trial.
Novel insights into the development and maintenance of the blood-brain barrier.
Transverse myelitis following combined spinal-epidural anesthesia.
The structure and function of the S1P1 receptor.
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials
Reliability and Validity of Ratings of Perceived Exertion in Persons with Multiple Sclerosis.

Pages